The Chemours Company (CC) reported a net loss of $29 million, or 19 cents per share, for the first quarter of 2026, compared to a net loss of $5 million, or 3 cents per share, in the same period last year. However, adjusted earnings of 5 cents per share surpassed the Zacks Consensus Estimate of a loss of 5 cents, surprising analysts who had anticipated weaker results.
Revenue Misses Estimates Despite Slight Growth
Net sales for the quarter reached $1.381 billion, a 1% increase year-over-year, but fell short of the consensus estimate of $1.4026 billion. The growth was driven by a 2% increase in pricing and a 3% favorable currency impact, partially offset by a 4% decline in volumes. Adjusted EBITDA rose 2% to $169 million, supported by higher pricing and currency benefits, which outweighed higher costs and lower sales volumes in the Advanced Performance Materials and Titanium Technologies segments.
Also read: Soybeans Slide on Crude Oil Pressure as US-Iran Deal Hopes Weigh on Markets
Segment Performance: Mixed Results Across Divisions
The Titanium Technologies division reported revenues of $559 million, a 6% decline year-over-year, though it beat internal estimates of $543.3 million. The drop was driven by a 7% decrease in global volumes and a 2% decline in pricing, partially offset by a 3% favorable currency impact.
In contrast, the Thermal & Specialized Solutions segment posted a 22% revenue increase to $568 million, nearly in line with estimates. Growth was fueled by an 11% price increase and a 9% volume rise, largely due to strong automotive Freon refrigerant sales in North America and the ongoing transition to Opteon refrigerants.
Also read: Cotton Futures Pare Early Losses but Close Lower as Crude Oil Plunges on US-Iran Talks
The Advanced Performance Materials unit saw revenues fall 17% to $243 million, missing estimates of $256.5 million. The decline was attributed to a 19% volume drop, primarily due to the Washington Works plant outage and the closure of the Capstone line in late 2025.
Financial Health and Cash Flow Improvements
Operating cash usage improved to $44 million from $112 million in the year-ago quarter, reflecting better working capital management. Capital expenditures were $49 million, down from $84 million. Free cash flow usage narrowed to $93 million from $196 million. As of March 31, 2026, Chemours held consolidated gross debt of $4.2 billion, with net debt of $3.6 billion after subtracting $563 million in cash. Total liquidity stood at $1.5 billion.
Outlook for Q2 and Full Year 2026
For the second quarter, Chemours expects consolidated net sales to increase 15-20% sequentially, driven by seasonal trends. Adjusted EBITDA is projected between $220 million and $250 million. The company also anticipates free cash flow of at least $100 million in Q2.
For the full year, Chemours maintains its guidance of 3-5% net sales growth and adjusted EBITDA between $800 million and $900 million. Capital expenditures are expected in the range of $275-$325 million, with free cash flow conversion above 20%.
Stock Performance and Market Context
Chemours shares have surged 117.1% over the past year, significantly outperforming the broader industry’s 25.1% gain. The stock’s strong performance reflects investor optimism about the company’s turnaround and cost-saving initiatives, despite ongoing challenges in certain segments.
Conclusion
Chemours’ Q1 results highlight a mixed operating environment: earnings beat expectations, but revenue fell short. The company’s outlook for Q2 and the full year suggests confidence in a seasonal rebound, particularly in Thermal & Specialized Solutions. However, the continued weakness in Advanced Performance Materials and Titanium Technologies warrants close monitoring. Investors should weigh the strong stock performance against lingering operational risks.
FAQs
Q1: Why did Chemours’ revenue miss estimates despite an earnings beat?
The revenue miss was primarily due to lower-than-expected volumes in the Advanced Performance Materials and Titanium Technologies segments, which offset pricing gains and currency benefits. The earnings beat was driven by better cost control and favorable currency impacts.
Q2: What is the outlook for Chemours’ Thermal & Specialized Solutions segment?
The segment is expected to see sequential net sales growth in the low-to-mid-teens percentage range in Q2, driven by seasonal demand for refrigerants and the continued transition to Opteon products. Adjusted EBITDA is projected between $210 million and $225 million.
Q3: How has Chemours’ stock performed recently, and what does it signal?
Chemours shares have gained 117% over the past year, far outpacing the industry average. This suggests strong investor confidence in the company’s restructuring and growth strategy, though the stock’s valuation may already reflect much of the anticipated improvement.
